{"transactions":[{"id":708296,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-16T16:39:47.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":97000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":97000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":97000},"source":{"system":"sec-edgar","filing":"0002018150-26-000003","document":"form4-07162026_040743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815026000003/form4-07162026_040743.xml","form_type":"4"}},{"id":709247,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-16T01:32:40.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":14150,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001237419-26-000003","document":"form4-07162026_010736.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000123741926000003/form4-07162026_010736.xml","form_type":"4"}},{"id":709246,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T20:32:32.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":93000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":93000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0002017800-26-000003","document":"form4-07152026_080727.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780026000003/form4-07152026_080727.xml","form_type":"4"}},{"id":709983,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":2741,"kind":"person","name":"STOVER JACK E","position":1,"cik":"0001203603","reported_name":"STOVER JACK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T01:57:35.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":14150,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001203603-26-000003","document":"form4-07152026_010731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000120360326000003/form4-07152026_010731.xml","form_type":"4"}},{"id":709982,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T00:26:20.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":274000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":274000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":274000},"source":{"system":"sec-edgar","filing":"0001681955-26-000002","document":"form4-07152026_120715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000168195526000002/form4-07152026_120715.xml","form_type":"4"}},{"id":709981,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30608,"kind":"person","name":"Redfield Robert","position":1,"cik":"0002018274","reported_name":"Redfield Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T00:23:52.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":84000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0002018274-26-000003","document":"form4-07152026_120748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201827426000003/form4-07152026_120748.xml","form_type":"4"}},{"id":709980,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30607,"kind":"person","name":"Parker Charles Nolan","position":1,"cik":"0002125562","reported_name":"Parker Charles Nolan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T00:22:50.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":90000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0002125562-26-000005","document":"form4-07152026_120746.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000212556226000005/form4-07152026_120746.xml","form_type":"4"}},{"id":709979,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30606,"kind":"person","name":"Shoemaker Mary Teresa","position":1,"cik":"0001813552","reported_name":"Shoemaker Mary Teresa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T00:22:11.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":14150,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001813552-26-000004","document":"form4-07152026_120707.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000181355226000004/form4-07152026_120707.xml","form_type":"4"}},{"id":709978,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30605,"kind":"person","name":"Clarke Trafford","position":1,"cik":"0001958857","reported_name":"Clarke Trafford","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T00:21:11.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":14150,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001958857-26-000003","document":"form4-07152026_120706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000195885726000003/form4-07152026_120706.xml","form_type":"4"}},{"id":709977,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30604,"kind":"person","name":"Leaman John Harold","position":1,"cik":"0001586657","reported_name":"Leaman John Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-15T00:19:32.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":14150,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001586657-26-000003","document":"form4-07152026_120728.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000158665726000003/form4-07152026_120728.xml","form_type":"4"}},{"id":799169,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrants (right to buy)","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":1793187,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain investors (the \"Investors\"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the \"Closing Date\") Series A warrants, Series B warrants, and Series C warrants (collectively, the \"Warrants\") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1793187,"derivative":{"exercise_price":1.673,"underlying":"Common Stock","underlying_shares":1793187},"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":799168,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":597729,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain investors (the \"Investors\"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the \"Closing Date\") Series A warrants, Series B warrants, and Series C warrants (collectively, the \"Warrants\") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":597729,"derivative":{"exercise_price":1.673,"underlying":"Common Stock","underlying_shares":597729},"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":799167,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":597729,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain investors (the \"Investors\"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the \"Closing Date\") Series A warrants, Series B warrants, and Series C warrants (collectively, the \"Warrants\") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":597729,"derivative":{"exercise_price":1.673,"underlying":"Common Stock","underlying_shares":597729},"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":799166,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":597729,"price":1.67,"value":998207.43,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1203250,"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":812818,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30607,"kind":"person","name":"Parker Charles Nolan","position":1,"cik":"0002125562","reported_name":"Parker Charles Nolan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-08T18:47:50.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":104544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":104544,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":104544},"source":{"system":"sec-edgar","filing":"0002125562-26-000004","document":"form4-04082026_060446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000212556226000004/form4-04082026_060446.xml","form_type":"4"}},{"id":812817,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30607,"kind":"person","name":"Parker Charles Nolan","position":1,"cik":"0002125562","reported_name":"Parker Charles Nolan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-08T18:47:50.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":61571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":61571,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":61571},"source":{"system":"sec-edgar","filing":"0002125562-26-000004","document":"form4-04082026_060446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000212556226000004/form4-04082026_060446.xml","form_type":"4"}},{"id":812816,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30607,"kind":"person","name":"Parker Charles Nolan","position":1,"cik":"0002125562","reported_name":"Parker Charles Nolan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-08T18:47:50.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":32406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":32406,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":32406},"source":{"system":"sec-edgar","filing":"0002125562-26-000004","document":"form4-04082026_060446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000212556226000004/form4-04082026_060446.xml","form_type":"4"}},{"id":812815,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30607,"kind":"person","name":"Parker Charles Nolan","position":1,"cik":"0002125562","reported_name":"Parker Charles Nolan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-08T18:47:50.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":15393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":15393,"source":{"system":"sec-edgar","filing":"0002125562-26-000004","document":"form4-04082026_060446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000212556226000004/form4-04082026_060446.xml","form_type":"4"}},{"id":851708,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30605,"kind":"person","name":"Clarke Trafford","position":1,"cik":"0001958857","reported_name":"Clarke Trafford","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:22:52.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":33435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":33435,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":33435},"source":{"system":"sec-edgar","filing":"0001958857-26-000002","document":"form4-03102026_110349.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000195885726000002/form4-03102026_110349.xml","form_type":"4"}},{"id":851709,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:21:59.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":31258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":31258,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":31258},"source":{"system":"sec-edgar","filing":"0001237419-26-000002","document":"form4-03102026_110356.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000123741926000002/form4-03102026_110356.xml","form_type":"4"}},{"id":851707,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30604,"kind":"person","name":"Leaman John Harold","position":1,"cik":"0001586657","reported_name":"Leaman John Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:20:43.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":33435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":33435,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":33435},"source":{"system":"sec-edgar","filing":"0001586657-26-000002","document":"form4-03102026_110339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000158665726000002/form4-03102026_110339.xml","form_type":"4"}},{"id":851706,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:19:05.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":231336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":231336,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":231336},"source":{"system":"sec-edgar","filing":"0001681955-26-000001","document":"form4-03102026_110302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000168195526000001/form4-03102026_110302.xml","form_type":"4"}},{"id":851705,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:18:25.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":118367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":118367,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":118367},"source":{"system":"sec-edgar","filing":"0002018150-26-000002","document":"form4-03102026_110321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815026000002/form4-03102026_110321.xml","form_type":"4"}},{"id":851704,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:17:04.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":96899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":96899,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":96899},"source":{"system":"sec-edgar","filing":"0002017800-26-000001","document":"form4-03102026_110301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780026000001/form4-03102026_110301.xml","form_type":"4"}},{"id":851703,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":2741,"kind":"person","name":"STOVER JACK E","position":1,"cik":"0001203603","reported_name":"STOVER JACK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:16:20.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":33435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":33435,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":33435},"source":{"system":"sec-edgar","filing":"0001203603-26-000001","document":"form4-03102026_110316.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000120360326000001/form4-03102026_110316.xml","form_type":"4"}},{"id":851702,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30608,"kind":"person","name":"Redfield Robert","position":1,"cik":"0002018274","reported_name":"Redfield Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:15:00.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":108854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":108854,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":108854},"source":{"system":"sec-edgar","filing":"0002018274-26-000002","document":"form4-03102026_110357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201827426000002/form4-03102026_110357.xml","form_type":"4"}},{"id":851701,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30606,"kind":"person","name":"Shoemaker Mary Teresa","position":1,"cik":"0001813552","reported_name":"Shoemaker Mary Teresa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:12:00.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":33435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":33435,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":33435},"source":{"system":"sec-edgar","filing":"0001813552-26-000002","document":"form4-03102026_110357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000181355226000002/form4-03102026_110357.xml","form_type":"4"}},{"id":968034,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30604,"kind":"person","name":"Leaman John Harold","position":1,"cik":"0001586657","reported_name":"Leaman John Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:23:54.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":16234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":16234,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":16234},"source":{"system":"sec-edgar","filing":"0001586657-25-000008","document":"form4-12162025_111250.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000158665725000008/form4-12162025_111250.xml","form_type":"4"}},{"id":968033,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30604,"kind":"person","name":"Leaman John Harold","position":1,"cik":"0001586657","reported_name":"Leaman John Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T23:23:54.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":4058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":4058,"source":{"system":"sec-edgar","filing":"0001586657-25-000008","document":"form4-12162025_111250.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000158665725000008/form4-12162025_111250.xml","form_type":"4"}},{"id":968032,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30605,"kind":"person","name":"Clarke Trafford","position":1,"cik":"0001958857","reported_name":"Clarke Trafford","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:22:44.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":24629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":24629,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":24629},"source":{"system":"sec-edgar","filing":"0001958857-25-000007","document":"form4-12162025_111241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000195885725000007/form4-12162025_111241.xml","form_type":"4"}},{"id":968031,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30605,"kind":"person","name":"Clarke Trafford","position":1,"cik":"0001958857","reported_name":"Clarke Trafford","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T23:22:44.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":6157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":6157,"source":{"system":"sec-edgar","filing":"0001958857-25-000007","document":"form4-12162025_111241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000195885725000007/form4-12162025_111241.xml","form_type":"4"}},{"id":968030,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:21:50.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":19496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":19496,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":19496},"source":{"system":"sec-edgar","filing":"0001237419-25-000004","document":"form4-12162025_111247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000123741925000004/form4-12162025_111247.xml","form_type":"4"}},{"id":968029,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T23:21:50.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":4874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":109222,"source":{"system":"sec-edgar","filing":"0001237419-25-000004","document":"form4-12162025_111247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000123741925000004/form4-12162025_111247.xml","form_type":"4"}},{"id":968028,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30606,"kind":"person","name":"Shoemaker Mary Teresa","position":1,"cik":"0001813552","reported_name":"Shoemaker Mary Teresa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:20:57.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":24629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":24629,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":24629},"source":{"system":"sec-edgar","filing":"0001813552-25-000005","document":"form4-12162025_111254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000181355225000005/form4-12162025_111254.xml","form_type":"4"}},{"id":968027,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30606,"kind":"person","name":"Shoemaker Mary Teresa","position":1,"cik":"0001813552","reported_name":"Shoemaker Mary Teresa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T23:20:57.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":6157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":6292,"source":{"system":"sec-edgar","filing":"0001813552-25-000005","document":"form4-12162025_111254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000181355225000005/form4-12162025_111254.xml","form_type":"4"}},{"id":968026,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":2741,"kind":"person","name":"STOVER JACK E","position":1,"cik":"0001203603","reported_name":"STOVER JACK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:20:09.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":24629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":24629,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":24629},"source":{"system":"sec-edgar","filing":"0001203603-25-000006","document":"form4-12162025_111205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000120360325000006/form4-12162025_111205.xml","form_type":"4"}},{"id":968025,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":2741,"kind":"person","name":"STOVER JACK E","position":1,"cik":"0001203603","reported_name":"STOVER JACK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T23:20:09.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":6157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":6165,"source":{"system":"sec-edgar","filing":"0001203603-25-000006","document":"form4-12162025_111205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000120360325000006/form4-12162025_111205.xml","form_type":"4"}},{"id":968024,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:17:27.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":147771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":147771,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":147771},"source":{"system":"sec-edgar","filing":"0001681955-25-000004","document":"form4-12162025_111223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000168195525000004/form4-12162025_111223.xml","form_type":"4"}},{"id":968023,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:17:27.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":36943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":171130,"source":{"system":"sec-edgar","filing":"0001681955-25-000004","document":"form4-12162025_111223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000168195525000004/form4-12162025_111223.xml","form_type":"4"}},{"id":968022,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:16:22.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":73886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":73886,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":73886},"source":{"system":"sec-edgar","filing":"0002018150-25-000004","document":"form4-12162025_111219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815025000004/form4-12162025_111219.xml","form_type":"4"}},{"id":968021,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Common Stock","published_at":"2025-12-16T23:16:22.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":18471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":115971,"source":{"system":"sec-edgar","filing":"0002018150-25-000004","document":"form4-12162025_111219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815025000004/form4-12162025_111219.xml","form_type":"4"}},{"id":968020,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30608,"kind":"person","name":"Redfield Robert","position":1,"cik":"0002018274","reported_name":"Redfield Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:15:29.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":65676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":65676,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":65676},"source":{"system":"sec-edgar","filing":"0002018274-25-000004","document":"form4-12162025_111226.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201827425000004/form4-12162025_111226.xml","form_type":"4"}},{"id":968019,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30608,"kind":"person","name":"Redfield Robert","position":1,"cik":"0002018274","reported_name":"Redfield Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:15:29.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":16419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":113919,"source":{"system":"sec-edgar","filing":"0002018274-25-000004","document":"form4-12162025_111226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201827425000004/form4-12162025_111226.xml","form_type":"4"}},{"id":968018,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:14:01.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":65676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":65676,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":65676},"source":{"system":"sec-edgar","filing":"0002017800-25-000004","document":"form4-12162025_111258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780025000004/form4-12162025_111258.xml","form_type":"4"}},{"id":968017,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:14:01.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":16419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":150606,"source":{"system":"sec-edgar","filing":"0002017800-25-000004","document":"form4-12162025_111258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780025000004/form4-12162025_111258.xml","form_type":"4"}},{"id":989049,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30604,"kind":"person","name":"Leaman John Harold","position":1,"cik":"0001586657","reported_name":"Leaman John Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-11-25T23:53:15.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":12770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."}],"balance_after":12770,"derivative":{"exercise_price":2.31,"expiration_date":"2035-11-21","underlying":"Common Stock","underlying_shares":12770},"source":{"system":"sec-edgar","filing":"0001586657-25-000007","document":"form4-11252025_111110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000158665725000007/form4-11252025_111110.xml","form_type":"4"}},{"id":1018778,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:10:29.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":22435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":22435,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":22435},"source":{"system":"sec-edgar","filing":"0002017800-25-000003","document":"form4-10162025_121025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201780025000003/form4-10162025_121025.xml","form_type":"4"}},{"id":1018777,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30608,"kind":"person","name":"Redfield Robert","position":1,"cik":"0002018274","reported_name":"Redfield Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:09:39.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":32406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":32406,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":32406},"source":{"system":"sec-edgar","filing":"0002018274-25-000003","document":"form4-10162025_121036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201827425000003/form4-10162025_121036.xml","form_type":"4"}},{"id":1018776,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:08:46.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":32406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":32406,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":32406},"source":{"system":"sec-edgar","filing":"0002018150-25-000003","document":"form4-10162025_121042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815025000003/form4-10162025_121042.xml","form_type":"4"}},{"id":1018775,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:07:54.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":64839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":64839,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":64839},"source":{"system":"sec-edgar","filing":"0001681955-25-000003","document":"form4-10162025_121051.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000168195525000003/form4-10162025_121051.xml","form_type":"4"}},{"id":1018774,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:06:31.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":11530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":11530,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":11530},"source":{"system":"sec-edgar","filing":"0001237419-25-000003","document":"form4-10162025_121028.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000123741925000003/form4-10162025_121028.xml","form_type":"4"}},{"id":1018773,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":2741,"kind":"person","name":"STOVER JACK E","position":1,"cik":"0001203603","reported_name":"STOVER JACK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:05:11.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":11530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":11530,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":11530},"source":{"system":"sec-edgar","filing":"0001203603-25-000005","document":"form4-10162025_121008.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000120360325000005/form4-10162025_121008.xml","form_type":"4"}},{"id":1018772,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30605,"kind":"person","name":"Clarke Trafford","position":1,"cik":"0001958857","reported_name":"Clarke Trafford","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:04:01.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":11530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":11530,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":11530},"source":{"system":"sec-edgar","filing":"0001958857-25-000006","document":"form4-10162025_121057.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000195885725000006/form4-10162025_121057.xml","form_type":"4"}},{"id":1018771,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30606,"kind":"person","name":"Shoemaker Mary Teresa","position":1,"cik":"0001813552","reported_name":"Shoemaker Mary Teresa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:03:04.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":11530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":11530,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":11530},"source":{"system":"sec-edgar","filing":"0001813552-25-000004","document":"form4-10162025_121000.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000181355225000004/form4-10162025_121000.xml","form_type":"4"}},{"id":1019557,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30604,"kind":"person","name":"Leaman John Harold","position":1,"cik":"0001586657","reported_name":"Leaman John Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-14T23:03:17.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":15609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."}],"balance_after":15609,"derivative":{"exercise_price":1.89,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":15609},"source":{"system":"sec-edgar","filing":"0001586657-25-000005","document":"form4-10142025_111013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000158665725000005/form4-10142025_111013.xml","form_type":"4"}},{"id":1104179,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30605,"kind":"person","name":"Clarke Trafford","position":1,"cik":"0001958857","reported_name":"Clarke Trafford","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-06-23T21:59:03.000Z","date":"2025-06-19","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":23000,"derivative":{"exercise_price":1.65,"exercise_date":"2026-06-19","expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-25-017997","document":"form4-06232025_090659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588925017997/form4-06232025_090659.xml","form_type":"4"}},{"id":1104178,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":2741,"kind":"person","name":"STOVER JACK E","position":1,"cik":"0001203603","reported_name":"STOVER JACK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-06-23T21:54:01.000Z","date":"2025-06-19","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":23000,"derivative":{"exercise_price":1.65,"exercise_date":"2026-06-19","expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-25-017996","document":"form4-06232025_090657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588925017996/form4-06232025_090657.xml","form_type":"4"}},{"id":1104177,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30606,"kind":"person","name":"Shoemaker Mary Teresa","position":1,"cik":"0001813552","reported_name":"Shoemaker Mary Teresa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-06-23T21:52:01.000Z","date":"2025-06-19","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":23000,"derivative":{"exercise_price":1.65,"exercise_date":"2026-06-19","expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-25-017995","document":"form4-06232025_090658.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588925017995/form4-06232025_090658.xml","form_type":"4"}},{"id":1104176,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2025-06-23T21:50:04.000Z","date":"2025-06-19","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":23000,"derivative":{"exercise_price":1.65,"exercise_date":"2026-06-19","expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-25-017992","document":"form4-06232025_090600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588925017992/form4-06232025_090600.xml","form_type":"4"}},{"id":1175878,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":2,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2025-04-09T00:32:34.000Z","date":"2025-04-02","kind":"other","planned":false,"acquired":false,"shares":2263.7451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock is convertible into 400 shares of the Issuer's common stock, subject to an issuance limitation that prohibits the holder from converting such shares of Series C Preferred Stock to the extent that, after giving effect to the issuance of shares of common stock after such conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) would beneficially own in excess of 19.99% of the shares of common stock of the Issuer then outstanding (the \"Beneficial Ownership Limitation\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of the Issuer's common stock, which was obtained on September 16, 2024, the shares of Series C Preferred are convertible into shares of common stock, subject to the Beneficial Ownership Limitation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C Preferred Stock do not expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock (\"Series C Preferred Stock\") reported in this Form 4 are presented on an after-reverse stock split basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":905497},"source":{"system":"sec-edgar","filing":"0001104659-25-033149","document":"tm2511901-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925033149/tm2511901-1_4seq1.xml","form_type":"4"}},{"id":1175877,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":2,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-09T00:32:34.000Z","date":"2025-04-02","kind":"other","planned":false,"acquired":false,"shares":605531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock (\"Series C Preferred Stock\") reported in this Form 4 are presented on an after-reverse stock split basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-033149","document":"tm2511901-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925033149/tm2511901-1_4seq1.xml","form_type":"4"}},{"id":1261001,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-02-19T23:23:35.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":96348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants became exercisable upon stockholder approval on February 17, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants do not expire."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001415889-25-004727","document":"form4-02192025_110231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588925004727/form4-02192025_110231.xml","form_type":"4"}},{"id":1261000,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-19T23:23:35.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":96348,"price":0.01,"value":963.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Stock was acquired by way of an exercise of Pre-Funded Warrants at an exercise price of $0.01 per Pre-Funded Warrant. The Pre-Funded warrants were acquired as part of Class B Units, with each Class B unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."}],"balance_after":104348,"source":{"system":"sec-edgar","filing":"0001415889-25-004727","document":"form4-02192025_110231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588925004727/form4-02192025_110231.xml","form_type":"4"}},{"id":1294715,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:03:50.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006409","document":"tm254427-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465925006409/tm254427-4_4seq1.xml","form_type":"4"}},{"id":1294714,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:03:50.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006409","document":"tm254427-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465925006409/tm254427-4_4seq1.xml","form_type":"4"}},{"id":1294698,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:02:52.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006408","document":"tm254427-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006408/tm254427-3_4seq1.xml","form_type":"4"}},{"id":1294697,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:02:52.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006408","document":"tm254427-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006408/tm254427-3_4seq1.xml","form_type":"4"}},{"id":1294696,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:01:45.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006407","document":"tm254427d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006407/tm254427d2_4seq1.xml","form_type":"4"}},{"id":1294695,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:01:45.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006407","document":"tm254427d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006407/tm254427d2_4seq1.xml","form_type":"4"}},{"id":1294694,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:00:08.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006406","document":"tm254427-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006406/tm254427-1_4seq1.xml","form_type":"4"}},{"id":1294693,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:00:08.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006406","document":"tm254427-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006406/tm254427-1_4seq1.xml","form_type":"4"}},{"id":1405559,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":47995,"kind":"person","name":"Greenwood Luba","position":1,"cik":"0001853815","reported_name":"Greenwood Luba","relationship":{"director":true}}],"security":"Stock Option (Right to Purchase)","published_at":"2024-09-17T21:12:11.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":164000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."}],"balance_after":164000,"derivative":{"exercise_price":0.34,"expiration_date":"2034-09-16","underlying":"Common Stock","underlying_shares":164000},"source":{"system":"sec-edgar","filing":"0000929638-24-003160","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824003160/form4.xml","form_type":"4"}},{"id":1439000,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-08-07T19:47:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":67500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the \"Common Stock\") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis."}],"balance_after":134187,"source":{"system":"sec-edgar","filing":"0000929638-24-002743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824002743/form4.xml","form_type":"4/A","original_submission_date":"2024-04-03"}},{"id":1438999,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-07T19:46:24.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":67500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the \"Common Stock\") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis."}],"balance_after":134187,"source":{"system":"sec-edgar","filing":"0000929638-24-002742","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824002742/form4.xml","form_type":"4/A","original_submission_date":"2024-04-03"}},{"id":1473568,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":83447,"kind":"person","name":"Guerin Mark Patrick","position":1,"cik":"0001607714","reported_name":"Guerin Mark Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Units","published_at":"2024-06-20T20:25:24.000Z","date":"2024-06-18","kind":"exercise","planned":false,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary"}],"balance_after":5500,"derivative":{"underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001415889-24-017636","document":"form4-06202024_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924017636/form4-06202024_080620.xml","form_type":"4"}},{"id":1473567,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":83447,"kind":"person","name":"Guerin Mark Patrick","position":1,"cik":"0001607714","reported_name":"Guerin Mark Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-06-20T20:25:24.000Z","date":"2024-06-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":2221,"price":0.47,"value":1043.87,"ownership":{"direct":true},"balance_after":39255,"source":{"system":"sec-edgar","filing":"0001415889-24-017636","document":"form4-06202024_080620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924017636/form4-06202024_080620.xml","form_type":"4"}},{"id":1473566,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":83447,"kind":"person","name":"Guerin Mark Patrick","position":1,"cik":"0001607714","reported_name":"Guerin Mark Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-06-20T20:25:24.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":41476,"source":{"system":"sec-edgar","filing":"0001415889-24-017636","document":"form4-06202024_080620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924017636/form4-06202024_080620.xml","form_type":"4"}},{"id":1550722,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30608,"kind":"person","name":"Redfield Robert","position":1,"cik":"0002018274","reported_name":"Redfield Robert","relationship":{"officer":true,"officer_title":"Acting Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:07:09.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":97500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025.  Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis."}],"balance_after":97500,"source":{"system":"sec-edgar","filing":"0000929638-24-001366","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001366/form4.xml","form_type":"4"}},{"id":1550721,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"officer":true,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-04T00:04:16.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":503227,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the \"Merger\"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share."}],"balance_after":503227,"derivative":{"exercise_price":0.01,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":503227},"source":{"system":"sec-edgar","filing":"0000929638-24-001364","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001364/form4.xml","form_type":"4"}},{"id":1550720,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"officer":true,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-04T00:04:16.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":333136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the \"Merger\"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share."}],"balance_after":333136,"derivative":{"exercise_price":0.07,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":333136},"source":{"system":"sec-edgar","filing":"0000929638-24-001364","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001364/form4.xml","form_type":"4"}},{"id":1550719,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"officer":true,"officer_title":"Chief Science Officer Virology"}}],"security":"Common Stock","published_at":"2024-04-04T00:04:16.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":97500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025.  Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\"), par value $0.01 per share (\"Common Stock\"), on a one-for-one basis."}],"balance_after":97500,"source":{"system":"sec-edgar","filing":"0000929638-24-001364","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001364/form4.xml","form_type":"4"}},{"id":1550718,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30383,"kind":"person","name":"CAUTREELS WERNER","position":1,"cik":"0001237419","reported_name":"CAUTREELS WERNER","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:03:08.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025.  Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000929638-24-001362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001362/form4.xml","form_type":"4"}},{"id":1550717,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":4801.1144,"ownership":{"direct":false,"nature":"By Viriom, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"shares","element":"transactionShares","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":4801.1144,"derivative":{"underlying":"Common Stock","underlying_shares":48011144},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550716,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":2584.3663,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"shares","element":"transactionShares","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2584.3663,"derivative":{"underlying":"Common Stock","underlying_shares":25843663},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550715,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":194.6223,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."}],"balance_after":194.6223,"derivative":{"underlying":"Common Stock","underlying_shares":1946223},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550714,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":3802890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share."}],"balance_after":3802890,"derivative":{"exercise_price":0.07,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":3802890},"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550713,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":1645100,"ownership":{"direct":false,"nature":"By Viriom, Inc."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1645100,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550712,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":885532,"ownership":{"direct":false,"nature":"By TPAV, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":885532,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550711,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":67550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis."}],"balance_after":134187,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550710,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":1,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":true,"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:01:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":66687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."}],"balance_after":66687,"source":{"system":"sec-edgar","filing":"0000929638-24-001360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001360/form4.xml","form_type":"4"}},{"id":1550709,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Series C Preferred Stock","published_at":"2024-04-03T23:59:53.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":4801.1144,"ownership":{"direct":false,"nature":"By Viriom, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"shares","element":"transactionShares","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":4801.1144,"derivative":{"underlying":"Common Stock","underlying_shares":48011144},"source":{"system":"sec-edgar","filing":"0000929638-24-001358","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001358/form4.xml","form_type":"4"}},{"id":1550708,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Series C Preferred Stock","published_at":"2024-04-03T23:59:53.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":194.6223,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations."}],"balance_after":194.6223,"derivative":{"underlying":"Common Stock","underlying_shares":1946223},"source":{"system":"sec-edgar","filing":"0000929638-24-001358","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001358/form4.xml","form_type":"4"}},{"id":1550707,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-03T23:59:53.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":3802890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share."}],"balance_after":3802890,"derivative":{"exercise_price":0.07,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":3802890},"source":{"system":"sec-edgar","filing":"0000929638-24-001358","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001358/form4.xml","form_type":"4"}},{"id":1550706,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-04-03T23:59:53.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":1645100,"ownership":{"direct":false,"nature":"By Viriom, Inc."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1645100,"source":{"system":"sec-edgar","filing":"0000929638-24-001358","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001358/form4.xml","form_type":"4"}},{"id":1550705,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-04-03T23:59:53.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":67550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis."}],"balance_after":134187,"source":{"system":"sec-edgar","filing":"0000929638-24-001358","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001358/form4.xml","form_type":"4"}},{"id":1550704,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30609,"kind":"person","name":"Dukes Iain D.","position":1,"cik":"0001681955","reported_name":"Dukes Iain D.","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-04-03T23:59:53.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":66687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in connection with the acquisition (the \"Merger\") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share (\"Common Stock\"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."}],"balance_after":66687,"source":{"system":"sec-edgar","filing":"0000929638-24-001358","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001358/form4.xml","form_type":"4"}},{"id":1575090,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":83447,"kind":"person","name":"Guerin Mark Patrick","position":1,"cik":"0001607714","reported_name":"Guerin Mark Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Restricted Stock Units","published_at":"2024-03-15T21:40:15.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":8666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 13, 2023 the reporting person was granted 26,000 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 13, 2023 the reporting person was granted 26,000 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."}],"balance_after":17334,"derivative":{"underlying":"Common Stock","underlying_shares":8666},"source":{"system":"sec-edgar","filing":"0001415889-24-008142","document":"form4-03152024_090303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924008142/form4-03152024_090303.xml","form_type":"4"}},{"id":1575089,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":83447,"kind":"person","name":"Guerin Mark Patrick","position":1,"cik":"0001607714","reported_name":"Guerin Mark Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2024-03-15T21:40:15.000Z","date":"2024-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2591,"price":0.9,"value":2331.9,"ownership":{"direct":true},"balance_after":35976,"source":{"system":"sec-edgar","filing":"0001415889-24-008142","document":"form4-03152024_090303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924008142/form4-03152024_090303.xml","form_type":"4"}},{"id":1575088,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":83447,"kind":"person","name":"Guerin Mark Patrick","position":1,"cik":"0001607714","reported_name":"Guerin Mark Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2024-03-15T21:40:15.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":8666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":38567,"source":{"system":"sec-edgar","filing":"0001415889-24-008142","document":"form4-03152024_090303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924008142/form4-03152024_090303.xml","form_type":"4"}},{"id":1575093,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":93015,"kind":"person","name":"Fruchtman Steven M","position":1,"cik":"0001631251","reported_name":"Fruchtman Steven M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CHIEF EXECUTIVE OFF"}}],"security":"Restricted Stock Units","published_at":"2024-03-15T21:36:28.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":23111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 13, 2023 the reporting person was granted 69,333 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 13, 2023 the reporting person was granted 69,333 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary."}],"balance_after":46222,"derivative":{"underlying":"Common Stock","underlying_shares":23111},"source":{"system":"sec-edgar","filing":"0001415889-24-008141","document":"form4-03152024_090321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588924008141/form4-03152024_090321.xml","form_type":"4"}}],"next_cursor":"2024-03-15T21:36:28.000000Z,1575093"}